[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glaucoma-open-angle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glaucoma-open-angle":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,40,71,99,123,159,181,205,229,255,277,297,320,340,369,389,415,445,469,495,520],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100521211","phase-4-travoprost-intraocular-implant--istent-infinite-100521211",false,"NCT06066645","Travoprost Intraocular Implant + iStent Infinite","Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite in Subjects With Open-angle Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n* diagnosis of open-angle glaucoma or ocular hypertension\n* qualifying IOP in the study eye\n\nExclusion Criteria:\n\n* unmedicated (washed out) IOP of \\>36 mmHg in the study eye\n* hypersensitivity to travoprost or any other components of the travoprost intraocular implant\n* vertical cup\u002Fdisc ratio \\> 0.8 in the study eye\n* best spectacle corrected visual acuity of worse than 20\u002F80 in either eye\n* any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.",[26],"Glaucoma, Open-Angle","RECRUITING","2026-05-29",{"date":30,"type":31},"2026-06-02","ACTUAL",{"date":33,"type":31},"2023-09-14",{"date":35,"type":20},"2028-02",{"name":37,"class":38},"Glaukos Corporation","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100538335","a-trial-of-hydrus-microstent-versus-goniotomy-100538335","NCT06289491","A Trial of Hydrus Microstent Versus Goniotomy","Randomized Trial of Hydrus Microstent Versus Goniotomy","Inclusion Criteria:\n\n* Visually significant cataract planned for surgery\n* Mild to moderate open-angle glaucoma, including pigmentary glaucoma and pseudoexfoliation glaucoma\n* Mild stage glaucoma includes glaucomatous optic neuropathy and visual field mean deviation better than -6.0 dB, with no points in the central 5 degrees \\\u003C15 dB\n* Moderate stage glaucoma includes: 1) glaucomatous optic neuropathy and visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5 degree points \\\u003C15 dB or 2) mean deviation -12.0 dB or better with 1 central 5 degree point \\\u003C15 dB\n* Medicated IOP between 10 to 31 mm Hg, inclusive, at time of decision for surgery\n* Willing and able to understand and provide informed consent\n* Willing and able to attend postoperative examinations per protocol schedule\n\nExclusion Criteria:\n\n* Prior argon laser trabeculoplasty, laser peripheral iridotomy, incisional glaucoma surgery, or cyclophotocoagulation\n* Selective laser trabeculoplasty within 90 days of study enrollment\n* Iridotrabecular contact for 180 degrees or greater\n* Peripheral anterior synechiae in nasal or inferior angle\n* Best corrected visual acuity worse than 20\u002F200\n* Phacodonesis on pre-operative examination\n* Vitreous in anterior chamber on pre-operative examination\n* Nanophthalmos\n* Anti-platelet and anticoagulant medications other than aspirin 81mg daily\n* Active treatment for another ophthalmic condition in either eye (e.g., anti-VEGF injections, steroids for corneal transplant)\n* Abnormality in study eye that could affect tonometry\n* Glaucoma diagnosis other than the above\n* Normal tension glaucoma\n* Conditions that can cause elevated episcleral venous pressure (e.g., Sturge-Weber syndrome, Graves disease, retrobulbar tumor)\n* History of uveitis in either eye\n* Inability to complete gonioscopy examination\n* Use of oral steroids within 90 days or anticipated use of oral steroids\n* Oral medications that can affect IOP, including oral carbonic anhydrase inhibitors such as acetazolamide and methazolamide\n* History of steroid-associated IOP elevation\n* Medically unfit for attending planned study visits\n* Involvement in another interventional research study","40 Years","85 Years",{"count":50,"type":20},243,[52],"NA","The goal of this clinical trial is to evaluate the comparative efficacy and safety of Hydrus Microstent, incisional goniotomy, and excisional goniotomy when combined with cataract surgery in patients with mild and moderate open-angle glaucoma. The main questions it aims to answer are:\n\n* How do the intraocular pressure lowering effects of these three microinvasive glaucoma surgeries compare?\n* How do the safety profiles of these three microinvasive glaucoma surgeries compare?\n\nParticipants will be randomized to one of these three microinvasive glaucoma surgeries in combination with cataract surgery.",[55,26],"Glaucoma",[57,58,59,60],"Incisional goniotomy","Excisional goniotomy","Hydrus Microstent","Goniotomy","2026-03-24",{"date":63,"type":31},"2026-03-30",{"date":65,"type":31},"2025-02-14",{"date":67,"type":20},"2029-04",{"name":69,"class":70},"Massachusetts Eye and Ear Infirmary","OTHER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":39},"100630334","combined-non-invasive-brain-and-visual-stimulation-for-vision-improvement-100630334","NCT07486323","Combined Non-Invasive Brain and Visual Stimulation for Vision Improvement","Evaluation of Combined Non-invasive Brain Stimulation (NIBS) and Visual Tetanic Stimulation (VTS) for Vision Enhancement: A Randomized, Single-blind, Cross-over Trial","Inclusion Criteria:\n\n* Age range from 18 to 80 years;\n* Diagnosis of primary open angle or normal tension glaucoma with relative scotoma in both eyes;\n* A relative scotoma defined as a Humphrey Field Analyser (HFA) threshold perimetry loss (mean deviation of -6dB) within the central 24 degree of the visual field for at least one eye;\n* Best-corrected distance visual acuity of 6\u002F12 or better (equivalent to 0.3 logMAR acuity or better to confirm that participant's central vision is preserved).\n* Stable vision and visual field loss for at least 3 months;\n* With a cognitive functional score of 22 or above in the Montreal Cognitive Assessment - Hong Kong version (HK-MoCA) (to confirm participant's intact cognitive function).\n\nExclusion Criteria:\n\n* Ocular diseases other than glaucoma (e.g. age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participant can hear the instructions clearly during assessments and training);\n* Severe medical problems (e.g. stroke, Parkinson's disease) or self-reported neurological (e.g. brain surgery, brain tumor, peripheral neuropathy), or cognitive disorders (e.g. diagnosed dementia or cognitive impairment);\n* Self-reported vestibular or cerebellar dysfunction, history of vertigo;\n* Using any medications for any neurological conditions or psychiatric drugs (e.g. sedative, hypnotic) that might interfere motor control;\n* Contraindications for non-invasive brain stimulation.","80 Years",{"count":80,"type":20},56,[52],"Glaucoma is a complex disease that can result in progressive vision loss. It is the second leading cause of blindness, accounting for 23% of permanent blindness in Hong Kong. There are no treatments that restore vision lost to glaucoma. This study will examine the effect of transcranial direct current stimulation (NIBS) on improving quality of life, visual function and functional performance in patients with peripheral field loss due to glaucoma.",[84],"Glaucoma Open-Angle",[86,87,88,89],"tDCS","transcranial electrical stimulation","visual tetanic stimulation","alpha frequency stimulation","NOT_YET_RECRUITING","2026-03-23",{"date":61,"type":31},{"date":94,"type":20},"2026-04-20",{"date":96,"type":20},"2027-07-10",{"name":98,"class":70},"The Hong Kong Polytechnic University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":39},"100581333","phase-4-safety-and-efficacy-of-idose-tr-with-cataract-surgery-vs-cataract-surgery-alone-100581333","NCT06848946","Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone","Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intracameral Implant) in Conjunction With Cataract Surgery vs. Cataract Surgery Alone","Inclusion Criteria:\n\n* Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.\n* OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)\n\nExclusion Criteria:\n\n* Active corneal inflammation or edema.\n* Retinal disorders not associated with glaucoma.","45 Years",{"count":108,"type":20},132,[23],"This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone",[112,113,114],"Glaucoma, Open-angle","Ocular Hypertension (OHT)","Phacoemulsification Cataract Surgery","2026-01-19",{"date":117,"type":31},"2026-01-21",{"date":119,"type":31},"2025-01-13",{"date":121,"type":20},"2027-06",{"name":37,"class":38},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":39},"100616072","dslt-in-normal-tension-glaucoma-ntg-asian-eyes-100616072","NCT07300852","DSLT in Normal Tension Glaucoma (NTG) Asian Eyes","The Effectiveness of DSLT in Asian Normal Tension Glaucoma Patients","Inclusion Criteria:\n\n* Asian descent\n* NTG diagnosis: glaucomatous optic neuropathy in patients with IOP measurements consistently lower than 21 mmHg\n* Mean deviation (MD) of the visual field between 0 to -12dB\n* No significant central vision loss within 5 degrees within 5th percentile\n* Age ≥20 years\n* NTG patients who are medically controlled on 1-3 medications and safe to wash out or IOP is still insufficient from medications and safe to washout\n* Shaffer grade II or more on 3 of the 4 quadrants\n* Central corneal thickness (CCT) 450-600µm\n* All participants are able to provide written informed consent before participation\n\nExclusion Criteria:\n\n* Angle closure glaucoma or narrow angle status post laser peripheral iridotomy (LPI), or any other open angle glaucoma excluding NTG\n* History of SLT within last 2 years\n* History intraocular surgery including refractive surgery, except for history of cataract surgery that has been greater than 1 year\n* Patients anticipating cataract surgery during the study follow-up period\n* Unable to have DSLT procedure due to pre-limbal findings\n* Any presence of relevant ocular diseases including retinal disease with no confirmed cure","20 Years",{"count":132,"type":20},40,[52],"The goal of this clinical trial is to evaluate the efficacy of direct selective laser trabeculoplasty (DSLT) or laser treatment in Asian patients with normal tension glaucoma. The main question it aims to answer is:\n\nDoes the DSLT reduce intraocular pressure (IOP) and medication use in Asian NTG subjects? Participants will attend routine follow-up visits with their eye surgeon and glaucoma testing such as optical coherence tomography (OCT) imaging and visual field test(s) after the laser study treatment.",[136,55,137,138],"Normal Tension Glaucoma (NTG)","Open Angle Glaucoma (OAG)","Glaucoma, Open Angle",[140,141,142,55,143,144,145,146,147,148,149],"DSLT","Direct Selective Laser Trabeculoplasty","NTG","Normal Tension Glaucoma","BELKIN Vision Eagle","Glaucoma laser treatment","Asian glaucoma","Intraocular pressure","SLT alternative","Glaucoma medications reduction","2025-12-20",{"date":152,"type":31},"2025-12-24",{"date":154,"type":20},"2026-01-01",{"date":156,"type":20},"2028-03-31",{"name":158,"class":70},"Ngoc Nguyen Inc.",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":165,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100507256","feasibility-clinical-evaluation-of-the-calibreye-system-100507256","NCT05885022","Feasibility Clinical Evaluation of the Calibreye System","Inclusion Criteria:\n\n* Open angle, pseudoexfoliative or pigmentary glaucoma\n* IOP at preoperative visit of ≥ 18mmHg and ≤ 45mmHg\n* Visual field mean deviation score of -3dB or worse\n* Area of healthy, free and mobile conjunctiva in the target quadrant\n* Shaffer angle grade ≥ 3 in the target quadrant\n\nExclusion Criteria:\n\n* Angle closure glaucoma\n* Congenital, neovascular or other secondary glaucomas\n* Previous intraocular surgery (with the exception of laser trabeculoplasty or uncomplicated phacoemulsification with IOL occurring \\> 3 months prior to the preoperative visit)\n* Previous glaucoma shunt\u002Fvalve in the target quadrant\n* Clinically significant inflammation or infection in the study eye within 30 days prior to the preoperative visit\n* History of corneal surgery, corneal opacities or corneal disease\n* Active diabetic retinopathy",true,{"count":167,"type":20},60,[52],"To evaluate the safety and feasibility of the Calibreye System in patients with open angle glaucoma.",[26],"2025-12-08",{"date":173,"type":31},"2025-12-15",{"date":175,"type":31},"2023-05-31",{"date":177,"type":20},"2028-12",{"name":179,"class":38},"Myra Vision Inc.",4,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":39},"100568744","electrical-stimulation-for-vision-neuroenhancement-in-glaucoma-100568744","NCT06685211","Electrical Stimulation for Vision Neuroenhancement in Glaucoma","A Randomized, Sham Controlled, Masked Study to Evaluate the Efficacy of Alternating Current Stimulation Using the Eyetronic System for the Treatment of Glaucoma","Inclusion Criteria:\n\n* Participant must be at least 18.\n* Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).\n* Participant's clinical diagnosis must be consistent with primary open angle glaucoma (including but not limited to normal tension, low tension or general open angle) characterized by the following features: Mean deviation (MD) worse than -6 but better than -20 on reliable Humphrey Visual Field 24-2 testing\n* Participant's eye pressure must be clinically stable, with IOP \\\u003C 18.\n* If a participant has two eyes meeting study criteria, the worse eye as determined by visual field index (VFI) or patient preference, will be deemed includable. If both eyes qualify and have the same VFI, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study.\n* Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he\u002Fshe cannot read the informed consent document, the document will be read to the participant in its entirety.\n\nExclusion Criteria:\n\n* Participant is unable to comply with study procedures or follow-up visits.\n* Participant has a history of ocular herpes zoster.\n* Participant has a requirement of acyclovir and\u002For related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.\n* Participant has evidence of corneal opacification or lack of optical clarity.\n* Participant has uveitis or other ocular inflammatory disease.\n* Participant is receiving systemic steroids or other immunosuppressive medications.\n* Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.\n* Participant is pregnant or lactating.\n* Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments.\n* Patients with opened skull, after trepanation or with heart and brain pacemaker.\n* Patients with implanted intracranial metals such as clippings, coilings, ventriculo-peritoneal shunts, endoprosthesis etc.\n* Patients with any skin damage in the area of electrode placement.\n* Children and comatose patients.\n* Patients with recent history of epileptic seizure.\n* Patients with uncontrolled high levels of blood pressure (\\\u003C160 mmHg) or uncontrolled high levels of intraocular pressure (\\\u003C27 mmHg).\n* Patients abusing drugs or alcohol.",{"count":189,"type":20},30,[52],"The purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtACS) using the EYETRONIC for the treatment in patients with glaucoma.",[55,84],[194,195],"glaucoma","open-angle glaucoma","2025-11-03",{"date":198,"type":31},"2025-11-04",{"date":200,"type":31},"2025-07-14",{"date":202,"type":20},"2027-12-31",{"name":204,"class":70},"Stanford University",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":39},"100363058","phase-4-the-effect-of-lumify-on-ocular-redness-intraocular-pressure-and-eyelid-position-in-glaucoma-patients-100363058","NCT04007276","The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients","The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of primary open angle glaucoma\n* Willing and able to give informed consent\n* Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use\n\nExclusion Criteria:\n\n* Pregnancy\n* Prisoners\n* Known allergy or sensitivities to brimonidine\n* No surgery within the past 6 months\n* No history of lid surgery or botox\n* Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator\n* Inability to sit comfortably for 30 minutes\n* Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study",{"count":167,"type":20},[23],"Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.",[55,26,216,217,218,219],"Glaucoma; Drugs","Droopy Eyelid","Ptosis","Glaucoma, Primary Open Angle","2025-09-30",{"date":222,"type":31},"2025-10-01",{"date":224,"type":20},"2026-11-10",{"date":226,"type":20},"2036-06-01",{"name":228,"class":70},"Tulane University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":39},"100604639","sctsc-versus-trabeculectomy-in-medically-uncontrolled-open-angle-glaucoma-in-pseudophakic-patients-100604639","NCT07152132","SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients","Slow Coagulation Trans-Scleral Cyclophotocoagulation Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients","Inclusion Criteria:\n\n* 1\\. Patients above 40 years old.\n\n  2\\. POAG who underwent previous uncomplicated cataract surgery with intraocular lens implantation.\n\n  3\\. Pseudophakic patients with medically uncontrolled glaucoma in spite of the use of two anti-glaucoma medications or intolerance to medical therapy.\n\n  4\\. Visual field defects in both the superior and inferior hemi-fields outside the central 5 degrees of fixation.\n\n  5\\. Mean deviation on perimetry ranges between -6 dB and -12 dB\n\nExclusion Criteria:\n\n* 1\\. Patients with history of previous glaucoma surgery. 2. Patients who have used topical steroids within the last three months. 3. Patients with significant media opacity, such as corneal opacity, that obstructs fundoscopic examination.\n\n  4\\. Patients with ocular diseases as uveitis. 5. Patients with severe ocular surface disorders as ocular cicatricial pemphigoid.\n\n  6\\. Aphakic patients. 7. Ocular interventions apart from YAG posterior capsulotomy.",{"count":237,"type":20},50,[52],"cyclodiode versus trabeculectomy with MMC in pseudophakic patients.",[138],[242,243,244,245],"SC-TSCPC","Trabeculectomy","OAG","Pseudophakic","2025-09-22",{"date":248,"type":31},"2025-09-25",{"date":250,"type":31},"2025-07-20",{"date":252,"type":20},"2026-12-30",{"name":254,"class":70},"Minia University",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":266,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":39},"100597826","feasibility-accuracy-and-reproducibility-of-virtual-reality-visual-field-testing-in-patients-with-glaucoma-100597826","NCT07063537","Feasibility, Accuracy, and Reproducibility of Virtual Reality Visual Field Testing in Patients With Glaucoma","Evaluation of the Accuracy and Reproducibility of Visual Field Testing Using a Virtual Reality Head-Mounted Device for Patients With Early, Moderate, and Advanced Glaucoma","Inclusion Criteria:\n\n* \\>18 years of age\n* diagnosis of primary open-angle glaucoma\n* ability to perform visual field testing\n* capacity to provide informed consent to research protocol\n\nExclusion Criteria:\n\n* diagnosis of secondary glaucoma or non-glaucomatous optic neuropathy\n* previous intraocular surgery (excluding cataract surgery and minimally invasive glaucoma surgery)\n* significant media opacity\n* pregnancy\n* seizure disorder\n* cardiac pacemaker\u002Fother implantable device\n* severe vertigo\u002Fbalance disorder",{"count":167,"type":20},[52],"The goal of this clinical trial is to evaluate the feasibility of using virtual reality based visual field testing to monitor glaucoma in a clinical setting. This will be done through comparison of a virtual reality (VR) based device to the current gold standard Ziess Humphrey Field Analyzer (HFA). The main questions the study aims to answer are:\n\n* Can both devices produce similar results in terms of detecting visual field defects and progression?\n* Does the stage (early, moderate, advanced) of glaucoma impact results between the two devices?\n\nParticipants will perform both a standard and a VR based visual field test at each visit, for a total of 5 visits.",[84],[267,268,55],"Virtual Reality","Visual Field","2025-07-02",{"date":200,"type":31},{"date":272,"type":31},"2024-12-14",{"date":274,"type":20},"2025-10",{"name":276,"class":70},"Nova Scotia Health Authority",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":39},"100487387","electrical-stimulation-for-the-treatment-of-optic-neuropathies-100487387","NCT05626426","Electrical Stimulation for the Treatment of Optic Neuropathies","An Open-Label Study to Evaluate the Safety and Efficacy of Repetitive, Transorbital Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies","rtACS","Inclusion Criteria:\n\n1. Participant must be at least 18.\n2. Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).\n3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false postivies do not exeed 20%.\n4. In the opinion of the investigator the participant's eye pressure must be clinically stable.\n5. If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study.\n6. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he\u002Fshe cannot read the informed consent document, the document will be read to the participant in its entirety.\n\nExclusion Criteria:\n\n1. Participant is unable to comply with study procedures or follow-up visits.\n2. Participant has a history of ocular herpes zoster.\n3. Participant has pathological nystagmus\n4. Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa.\n5. Participant has evidence of corneal opacification or lack of optical clarity.\n6. Participant has uveitis or other ocular inflammatory disease.\n7. Participant has any electric or electroinc implants such as a pacemaker.\n8. Participant has acute conjunctivitis.\n9. Participant has acute autoimmune disease.\n10. Participant is pregnant or lactating.\n11. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia.\n12. Unresected brain tumors\n13. Implanted intracranial magnetic metals (metallic implants in the head \u002F skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable\n14. Patients with any skin damage.\n15. Children and comatose patients.\n16. Patients with history of epileptic seizure within the last 10 years.\n17. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.\n18. Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and\u002For unable to confirm follow-up participation\n19. Prior participation in a vision training\u002Fstimulation study in the last 12 months",{"count":132,"type":20},[52],"The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.",[55,26,289],"Optic Nerve Diseases",{"date":291,"type":31},"2025-07-08",{"date":293,"type":31},"2023-02-27",{"date":295,"type":20},"2027-12",{"name":204,"class":70},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":21,"phases":306,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":39},"100590190","phase-2-evaluate-efficacy-and-safety-of-pa5108-ocular-implants-in-primary-open-angle-glaucoma-or-ocular-hypertension-100590190","NCT06964191","Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension","A Phase 2 Randomized, Multi-center, Parallel, Active-controlled Clinical Study to Evaluate the Safety and Efficacy of Intracameral PA5108 Ocular Implants in Patients With Primary Open-angle Glaucoma, or Ocular Hypertension","Key Inclusion Criteria:\n\n* Ability to provide informed consent and follow study instructions\n* 18 years of age or older\n* Diagnosis of open-angle glaucoma or ocular hypertension in both eyes\n* Qualifying IOPs across 2 visits following washout of IOP-lowering medication, if applicable\n* Qualifying best-corrected visual acuity BCVA using Early Treatment Diabetic Retinopathy Study (ETDRS) chart in study eye\n* Qualifying corneal endothelial cell density (CEDC) in the study eye\n\nKey Exclusion Criteria:\n\n* Pseudoexfoliation or pigment dispersion, narrow irido-corneal drainage angles, or existing peripheral anterior synechiae in the inferior angle either eye.\n* Advanced or severe glaucoma\n* Disqualifying central corneal thickness in either eye\n* Significant other ocular conditions that could prevent accurate assessment of IOP and corneal health\n* Uncontrolled medical conditions\n* Have previously received, any injectable glaucoma medication into the anterior chamber of the study eye\n* Have received intravitreal injections in the study eye within the last 3 months of the Screening Visit and anticipated need for an intravitreal injection during the course of the study\n* Unwilling or unable to discontinue, in either eye, soft contact lens wear at least 2 days and hard contact lens wear 1 week before scheduled study visits and on implant administration days",{"count":305,"type":20},75,[307],"PHASE2","The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.",[26,310],"Ocular Hypertension","2025-06-10",{"date":313,"type":31},"2025-06-13",{"date":315,"type":31},"2025-05-31",{"date":317,"type":20},"2026-11-15",{"name":319,"class":38},"PolyActiva Pty Ltd",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":165,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":21,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":39},"100352543","investigation-of-neurovascular-coupling-in-glaucoma-patients-and-healthy-subjects-100352543","NCT03870230","Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects","Inclusion criteria\n\nPatients with primary open angle glaucoma\n\n* Diagnosis of manifest primary open angle glaucoma defined as pathological optic disc appearance\n* Glaucoma hemifield test outside normal limits\n* Untreated IOP ≥ 21 mmHg on at least three measurements in the medical history\n* Mean deviation in the visual field test is less than or equal 10dB (for one group) OR more than 10dB (for the other group)\n\nPatients with normal tension glaucoma\n\n* Diagnosis of manifest normal tension glaucoma defined as pathological optic disc appearance\n* Glaucoma hemifield test outside normal limits\n* No evidence of untreated IOP \\> 20 mmHg in the medical history\n* Mean deviation in the visual field is less than or equal 10dB (for one group) OR more than 10dB (for the other group)\n\nPatients with ocular hypertension\n\n* Normal ophthalmic findings except presence of ocular hypertension defined as untreated IOP ≥ 21 mmHg on at least three measurements in the medical history\n* No signs of glaucomatous damage in the optic disc\n* or the glaucoma hemifield test\n\nHealthy control subjects\n\n* Normal ophthalmic findings\n* IOP \\\u003C 20 mmHg on least three measurements\n* No evidence of increased IOP in the medical history\n* No signs of glaucomatous damage in the optic disc\n* or the glaucoma hemifield test\n\nExclusion criteria\n\n* History of a severe medical condition as judged by the clinical investigator\n* Abuse of alcoholic beverages\n* Smoker\n* Participation in a clinical trial in the 3 weeks preceding the study\n* Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure\n* Intraocular surgery within the last 6 months\n* Ocular inflammation or infection within the last 3 months\n* History of epilepsia\n* Diabetes mellitus\n* Untreated hypertension with systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 95 mmHg\n* Pregnancy\n* Planned pregnancy or lactating",{"count":327,"type":20},120,[52],"Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to optic nerve head (ONH) damage and associated visual field defects. The main risk factor for glaucoma is elevated intraocular pressure (IOP). Reducing IOP slows down the progression of the disease as several large multicenter trials have shown. Some patients, however, still progress despite adequately controlled IOP. As such, there is considerable interest in approaches that rescue RGCs independent of IOP, a strategy called neuroprotection. Although this field was actively discovered in the last 20 years in the brain and the eye, no non-IOP related treatment is clinically available to date. Various approaches are currently studied in some detail. One interesting strategy focuses on the neurovascular unit.\n\nThe blood flow of the human retina is controlled by complex mechanisms that include myogenic, metabolic and hormonal factors. The high consumption of oxygen in the human retina is crucial for normal functioning of the organ. As in the brain, blood flow in the retina is also controlled by neurovascular coupling. This means that the retina increases its blood flow to regions in which neurons are activated. This is done in an effort to provide more oxygen and glucose to the active neurons. In the recent years evidence has accumulated that astrocytes play a key role in mediating this vasodilator signal.\n\nIn the brain, abnormalities in neurovascular coupling have been observed in diseases like stroke, hypertension, spinal-cord injury and Alzheimer's disease. This break-down of neurovascular coupling is considered to play a key role in neuronal death in these diseases. In the retina, abnormalities in neurovascular coupling have been observed in diseases as diabetes and glaucoma.\n\nMost of the data obtained in the human retina stem from a system that measures retinal vasodilatation during stimulation with flickering light. The investigators have previously shown that flicker stimulation of the retina is, however, also associated with a pronounced increase in retinal blood velocities. In this study the investigators employed laser Doppler velocimetry (LDV) for the measurement of retinal blood velocities, but this technique is not clinically applicable because it requires excellent fixation of the subject under study. In the present study, the investigators propose to use an alternative system for neurovascular coupling that they have developed recently. In this approach, the investigators use bi-directional Fourier-domain optical coherence tomography for the assessment of retinal blood flow. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology, OCT has become a standard tool in visualizing the retina and nowadays is considered also as a standard tool in the diagnosis of retinal disease. In the recent years, conventional time domain OCT was replaced by Fourier domain OCT providing significantly improved signal quality.\n\nThis bidirectional system overcomes the limitations of previously realized techniques, which include doubtful validity and limited reproducibility. In addition, pattern ERG, multifocal ERG and oscillatory potentials will be measured to allow for concomitant assessment of neural function.\n\nThe investigators seek to measure neurovascular coupling in the human retina in patients with early primary open angle glaucoma (POAG), normal tension glaucoma, ocular hypertension and a healthy control group. In order to obtain information on neurovascular coupling, both neuronal function as well as retinal blood flow need to be measured. In the present study, the investigators will employ pattern ERG, multifocal ERG as well as oscillatory potentials to assess the function of the inner retina. Retinal blood flow through major retinal arterial and venous branch vessels will be measured before, during and after flicker stimulation with the dual-beam bidirectional Fourier Domain Doppler OCT coupled to the commercially available Dynamic Vessel Analyzer (DVA) produced by IMEDOS, Jena, Germany, which provides adequate resolution to study the retinal circulation.",[26,143,310],"2025-05-20",{"date":333,"type":31},"2025-05-23",{"date":335,"type":31},"2017-12-01",{"date":337,"type":20},"2026-03",{"name":339,"class":70},"Medical University of Vienna",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":349,"phases":4,"briefSummary":350,"conditions":351,"keywords":354,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":39},"100282646","dresden-glaucoma-and-treatment-study-dgts-100282646","NCT02959242","Dresden Glaucoma and Treatment Study (DGTS)","Dresden Glaucoma and Treatment Study: Analysis to Assure the Quality of Follow-up and Therapy of Glaucoma Patients in a Tertiary University Hospital Glaucoma Service.","Inclusion Criteria:\n\n* manifest glaucoma, ocular Hypertension, glaucoma suspect\n\nExclusion Criteria:\n\n* under 18 years of age, corneal diseases",{"count":348,"type":20},10000,"OBSERVATIONAL","To assure the quality of follow-up and treatment, data of glaucoma patients are stored and evaluated after anonymisation.",[55,26,352,353],"Glaucoma, Angle-Closure","Glaucoma, Low Tension",[355,356,357,358,359],"Follow-up intervals","Treatment Efficiency","Laser Therapy","Glaucoma Surgery","Minimal Invasive Glaucoma Surgery (MIGS)","2025-02-03",{"date":362,"type":31},"2025-02-04",{"date":364,"type":4},"2006-01",{"date":366,"type":20},"2030-12",{"name":368,"class":70},"Technische Universität Dresden",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":21,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":39},"100578311","a-prospective-interventional-cohort-study-to-evaluate-the-efficacy-and-safety-of-the-aqualumen-a-novel-filtration-procedure-for-the-treatment-of-open-angle-glaucoma-100578311","NCT06809647","A Prospective Interventional Cohort Study to Evaluate the Efficacy and Safety of the AquaLumen, a Novel Filtration Procedure for the Treatment of Open Angle Glaucoma","Inclusion Criteria:\n\n* Moderate to severe open angle glaucoma\n* Central corneal thickness between 480 and 610 microns\n\nExclusion Criteria:\n\n* surgical history of corneal graft\n* presence of corneal opacities\n* Failed prior trabeculectomy",{"count":376,"type":20},10,[52],"The study will follow a group of patients with glaucoma disease that undergo a surgical procedure intended to reduce the intra-ocular pressure (IOP) for a period of one year.",[84],"2025-01-30",{"date":382,"type":31},"2025-02-05",{"date":384,"type":20},"2025-03-30",{"date":386,"type":20},"2026-08-30",{"name":388,"class":38},"PLU Ophthalmic",{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":397,"targetDuration":4,"studyType":21,"phases":399,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":39},"100531565","evaluation-of-phacogoniotomy-in-medically-controlled-poag-100531565","NCT06201455","Evaluation of Phacogoniotomy in Medically-controlled POAG","Efficacy of Phacogoniotomy in Medically-controlled Primary Open-angle Glaucoma With Cataract a Multicenter Non-inferiority Randomized Controlled Trial","ECO","Inclusion Criteria:\n\n1. 40 ≤ Age ≤ 85 years, gender unrestricted.\n2. Diagnosed with POAG.\n3. Controlled IOP under 1 to 4 topical hypotensive medications, IOP ≤ 24 mmHg\n4. Mean deviation (MD) for perimetry ≥ -16dB.\n5. Presence of clinically significant cataract and best-corrected visual acuity measured using the ETDRS chart ≤ 0.63.\n6. Voluntary participation of the patient in this study, signing an informed consent form, and agreeing to follow-up visits according to the study protocol.\n\nExclusion Criteria:\n\n1. Any history of intraocular surgery or ocular trauma.\n2. Presence of other types of glaucoma, including primary angle-closure glaucoma and various forms of secondary glaucoma (e.g. secondary angle-closure, pigmentary, steroid-induced, angle-recession, neovascular, inflammatory, and pseudoexfoliation syndrome).\n3. Presence of severe ocular diseases of various types that affect the acquisition of ocular parameters or interfere with perimetry.\n4. Axial length \\> 28 mm.\n5. Monophthalmia (best-corrected visual acuity of the non-study eye \\\u003C 0.01).\n6. Coexistence of severe systemic diseases affecting the entire body.\n7. Pregnant or lactating women.\n\n   * If both eyes of a patient meet the criteria, the eye with worse visual acuity will be selected for inclusion.",{"count":398,"type":20},100,[52],"The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are:\n\n* Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled POAG.\n* Whether the PEI+GT has value of health economics. Participants will be randomized to receive either PEI+GT or PEI+MED, and followed up with a 1-year period as a primary outcome.",[26,402,60],"Cataract Complicated",[26,404,60,405],"Cataract","Minimally invasive glaucoma surgery","2024-12-06",{"date":408,"type":31},"2024-12-11",{"date":410,"type":31},"2023-09-28",{"date":412,"type":20},"2029-12-31",{"name":414,"class":70},"Sun Yat-sen University",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":349,"phases":4,"briefSummary":424,"conditions":425,"keywords":426,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":39},"100442307","inflammatory-biomarkers-in-ocular-surface-in-primary-open-angle-glaucoma-or-ocular-hypertension-under-topical-prostaglandins-100442307","NCT05039684","Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins","Inflammatory Biomarkers in Ocular Surface in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Under Topical Prostaglandin Therapy","Inclusion Criteria:\n\n* Patients with primary open angle glaucoma or ocular hypertension as defined in Early Manifest Glaucoma Trial\n* \\> 18 years old\n* Signed informed consent\n* 3 or more months under monotherapy treatment with tafluprost 0.0015%, latanoprost 0.005% with BAK 0.2mg\u002Fml or latanoprost 0.005%.\n* Untreated patients with ocular hypertension must be treatment naïve for the pathology.\n* No presence or history of previous ocular diseases other than glaucoma or ocular hypertension, started before the use of hypotensive medication.\n\nExclusion Criteria:\n\n* Ocular surgery in the previous 6 months.\n* Any ocular surface disease not related to inclusion criteria or related issues active within the last 6 months.\n* Any topical treatment other than the evaluated in this study in the last 3 months.\n* In case of artificial teardrops use, only non conservative ones are allowed, with no more than 4 times per day use, and treatment must be suspended 5 days before inclusion.\n* Use of contact lenses in the las 4 weeks.\n* Any mental or physical disease that may prevent performing the required tests for the study.","99 Years",{"count":132,"type":20},"Glaucoma is a chronic optic neuropathy whose main modifiable risk factor is an abnormally elevated intraocular pressure. The aim of glaucoma treatment is to slow the progression of the disease by reducing intraocular pressure.\n\nProstaglandin derivatives are the most effective topical drugs in reducing intraocular pressure (IOP). Among these, latanoprost was the first agent of this type to be approved for use in patients with glaucoma or ocular hypertension.\n\nThese eye drops are available with and without preservatives. There are two commercial brands in our environment, Xalatan®, which contains 0.005% latanoprost and 0.2 mg\u002Fml benzalkonium chloride (BAK) and Monoprost®, which contains the same amount of latanoprost but does not carry a preservative. The prostaglandin analog with a lower concentration of active ingredient available in Spain without preservative is tafluprost 0.0015%, commercially available under the name Saflutan®.\n\nThe long-term use of hypotensive eye drops with preservatives generates changes in the ocular surface, such as instability of the tear film, conjunctival inflammation, subconjunctival fibrosis, apoptosis of the conjunctival epithelium and deterioration of the corneal surface, causing symptoms such as stinging, tearing, sensation foreign body, photophobia and blurred vision.\n\nThis research will evaluate the changes in the ocular surface and in the expression of inflammatory molecules that occur in the conjunctiva in patients with a diagnosis of glaucoma and ocular hypertension who are under ocular hypotensive treatment with tafluprost, comparing it with the two commercial preparations of latanoprost.\n\nThese three groups of patients will have a control group of patients with a diagnosis of ocular hypertension who will not have any topical hypotensive medication.",[26,310],[194,427,428,429,430,431,432,433,434,435],"prostaglandin","ocular hypertension","biomarker","inflammation","confocal in-vivo microscopy","cornea","tear film","conjunctiva","impression cytology","2024-10-30",{"date":438,"type":31},"2024-10-31",{"date":440,"type":31},"2021-10-01",{"date":442,"type":20},"2025-12",{"name":444,"class":70},"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA",{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":21,"phases":454,"briefSummary":455,"conditions":456,"keywords":457,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":39},"100487232","results-of-patients-with-glaucoma-undergoing-minimally-invasive-glaucoma-surgery-in-conjunction-with-cataract-surgery-100487232","NCT05624398","Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery","Visual Outcomes and Patient Satisfaction in Subjects With Stable Open-angle Glaucoma Undergoing Concurrent Minimally Invasive Glaucoma Surgery and IOL Implantation With an Extended-depth-of-focus IOL","Inclusion Criteria:\n\n* Male or female subjects 45 years of age or older\n* A visually significant age-related cataract in both eyes\n* Diagnosis of mild OAG\n\n  * VF characteristics consistent with glaucoma with mean deviation not worse than -6.00 dB and without fixation threatening scotoma AND\u002FOR with nerve abnormalities consistent with glaucoma (rim notching, rim thinning, disc hemorrhage, nerve fiber layer loss)\n  * Medicated IOP ≤25 mmHg on 1-3 hypotensive medications\n* Glaucoma must be judged as stable by investigator based on review of subject medical records\n\n  * Stable VF at least 1 year prior to surgery\n  * Stable nerve fiber layer at least 1 year prior to surgery\n  * IOP stable on current medication regimen at least 3 months prior to surgery\n* Shaffer grade of ≥ III in all angle quadrants\n* Potential of best corrected visual acuity at distance in the investigator's judgement of at least 0.1 logMAR (20\u002F25) postoperatively\n* Able and willing to comply with follow up visits\n* Understands and signs the informed consent\n* Both eyes of the subject should undergo surgery within 21 days of each other to ensure adequate timing for final visit window of 90 days ± 21 days post operatively\n\nExclusion Criteria:\n\n* Previous incisional glaucoma surgery or cilio-ablative surgery\n* Prior laser trabeculoplasty within 90 days of surgery\n* Pseudoexfoliative, angle closure, uveitic, congenital, traumatic, angle recession, or neovascular glaucoma.\n* Moderate glaucoma with VF mean deviation between -6.00 dB and -12.00 dB\n* Severe and\u002For progressive glaucoma defined as\n\n  * VF mean deviation worse than -12.00 dB\n  * Consistent worsening of visual field on review of subject medical records\n  * Consistent and progressive thinning of nerve fiber layer on review of subject medical records\n  * Uncontrolled IOP on maximum glaucoma medications\n  * Historically poor IOP control with medical therapy\n  * Severe focal notching of the optic nerve rim\n  * Expectation for future need of incisional glaucoma surgery\n* Ocular pathology or other medical condition which, in the investigator's judgment places the subject at increased risk of complications or significant vision loss during study period\n* Ocular pathology that in the investigator's judgment may impact visual acuity postoperatively, i.e., significant ocular surface disease, corneal scarring, blepharitis, epiretinal membrane, macular degeneration, history of significant ocular trauma with sequela, etc.\n* Pregnant or breastfeeding women\n* Prior refractive surgery e.g., LASIK, RK, PRK, etc.\n* Subjects with significant complications during surgical procedure e.g., broken capsule, Hydrus Microstent complication, will be exited from the trial\n* Subjects who experience visually significant complications related to the Hydrus Microstent during the study period will be exited from the trial",{"count":453,"type":20},25,[52],"This study is designed to determine how well patients with glaucoma can see following cataract surgery with a special type of lens called an extended-depth-of-focus (EDOF) lens. This lens is intended to reduced the patients need for glasses following cataract surgery. Patients will also undergo a minimally invasive type of glaucoma surgery using a special type of stent to reduce eye pressure, with the goal of better glaucoma control and the reduction in the need for medications to control eye pressure.",[26,404],[55,404,458,459],"Microstent","Premium IOL","2024-08-11",{"date":462,"type":31},"2024-08-13",{"date":464,"type":31},"2022-12-07",{"date":466,"type":20},"2025-05-01",{"name":468,"class":70},"Vold Vision P.L.L.C",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":21,"phases":479,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":376},"100470439","phase-3-nicotinamide-in-glaucoma-naming-a-randomised-placebo-controlled-multi-centre-phase-iii-trial-100470439","NCT05405868","Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial","A Phase III, Double-masked, Randomised, Placebo-controlled Trial Investigating the Safety and Efficacy of Nicotinamide (NAM) to Slow Visual Field Loss in Adults With Open-angle Glaucoma","NAMinG","Inclusion Criteria:\n\n1. Patients who have been recently diagnosed (within the last 12 months) with early to moderate open-angle glaucoma (OAG) in at least one eye (including primary OAG, normal tension glaucoma (NTG) and pseudoexfoliation glaucoma)\n2. Open angle on gonioscopy\n3. Adults aged 18 years or over\n4. Snellen visual acuity 6\u002F12 or better in at least one eye meeting the visual field (VF) criteria\n5. Visual Field (VF) mean deviation (MD) no worse than -12dB in either eye\n6. A negative pregnancy test result at the screening and baseline visit prior to randomisation for women of childbearing potential\n7. Ability to provide informed consent to participate\n8. Able and willing to attend trial visits and comply with trial procedures for the duration of the trial\n\nExclusion Criteria:\n\n1. Pigment dispersion glaucoma\n2. Pregnancy (or planned pregnancy during the trial) and\u002For breastfeeding\n3. Women of childbearing potential and male participants with a partner of childbearing potential not willing to use highly effective contraception for the duration of the trial treatment and for the time period specified following last trial treatment administration.\n4. Current treatment with either isoniazid, pyrazinamide, carbamazepine, phenobarbital or primidone\n5. Current liver disease or laboratory results with elevated levels of liver transaminases (AST or ALT \\>3 x ULN) at screening visit.\n6. Renal failure (eGFR \\\u003C30mL\u002Fmin\u002F1.73m²) at screening visit.\n7. Conditions affecting both eyes which may affect the Visual Field test result:\n\n   1. Diabetic retinopathy or any other retinal disease causing VF loss\n   2. Clinically relevant cataract (likely to require cataract surgery within the next 2 years)\n   3. Dementia or other non-glaucomatous neurological disease causing VF loss\n   4. Adnexal conditions causing VF loss (including but not limited to blepharochalasis)\n8. Diagnosed with cancer in the last 5 years (with exception of non-melanoma skin cancer).\n9. Any clinical condition that, in the investigator's opinion would make the participant unsuitable for the trial.\n10. Concurrently enrolled in any other interventional trial or participation in previous clinical trial of glaucoma.\n11. Current use of, and unwilling to abstain from, over-the-counter additional vitamin B3\u002FNAM oral supplements (including skin preparations such as ointments\u002Femulsions), Ginkgo Biloba and\u002For Coenzyme Q10 supplements, throughout the duration of their participation in the trial.",{"count":478,"type":20},496,[480],"PHASE3","Glaucoma is the leading cause of sight impairment and blindness worldwide. It is a long-term eye disease which can cause permanent loss of sight and sometimes blindness and affects 1 in 50 people over 50 years of age. Open-angle glaucoma (OAG) is the most common type of glaucoma. This tends to develop slowly over many years, caused by the drainage pathway in the eye gradually becoming blocked over time due to a build-up of fluid. This build-up causes pressure in the eye to increase (intra-ocular pressure (IOP)), which then damages the important nerve at the back of the eye called the optic nerve, resulting in vision loss. Current treatments offered for glaucoma (eye drops or laser surgery), aim to lower eye pressure and have shown to slow vision loss, however, visual disability and blindness rates remain unacceptably high and many patients continue to lose vision despite these treatments, suggesting that the optic nerve in some patients is more easily damaged. Recent research has looked at cells called 'mitochondria'. These cells produce most of the energy in the body, and the nerve cells in the eye need a lot of energy to function and survive. Nicotinamide (NAM) is a form of Vitamin B3 and evidence so far has shown that mitochondrial function can be improved with this treatment. The aim of this trial is to find out whether taking oral NAM when used with current standard treatment for lowering pressure in the eye, can reduce the amount of sight loss in recently diagnosed patients with OAG, and evaluate the long-term safety and effectiveness of NAM. The trial will use two groups of people recently diagnosed with glaucoma and who have normal care (drops or laser) to lower eye pressure. Using a method of randomisation (randomly allocated to each group using a computer system), one group will be given NAM and the other group will be given a placebo or 'dummy pill'. This is a double masked trial meaning the participant nor the Investigator will be told which treatment group patients have been allocated to.",[26],[484,485],"Nicotinamide","Vitamin B3","2024-05-07",{"date":488,"type":31},"2024-05-09",{"date":490,"type":31},"2024-01-18",{"date":492,"type":20},"2027-06-30",{"name":494,"class":70},"University College, London",{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":21,"phases":504,"briefSummary":505,"conditions":506,"keywords":507,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":39},"100493825","phase-3-efficacy-of-citicoline-eye-drops-2-on-visual-field-preservation-in-patients-with-open-angle-glaucoma-100493825","NCT05710198","Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma","A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma","Inclusion Criteria:\n\n1. Signed written informed consent.\n2. Age ≥ 18 years.\n3. Eyes with OAG, Pseudoexfoliation and pigmentary glaucoma will be included.\n4. Best Corrected Visual Acuity (BCVA) ≥ 0.5 for the study eye.\n5. Controlled IOP (≤ 18 mmHg, average of the last 3 measurements in the clinic) in the study eye.\n6. Visual field MD not worse than -12 dB at the latest assessment in the clinic for the study eye.\n7. Deteriorating MD at a rate between -0.5 dB\u002Fyear and -1.0 dB\u002Fyear, estimated from the latest VF tests collected in the clinic (at least 4) over a period during which incisional glaucoma surgery was not performed. Combinations of SITA Standard and Fast strategies (but not SITA Faster) is admissible. Patients who reach the desired minimum number of tests (4) with a mixture of SITA Standard\u002FFast and SITA Faster tests will need to perform additional replacement tests according to the prevalent strategy used in their series of VF (i.e. additional SITA Standard\u002FFast tests if ≤ 2 tests were SITA Faster; additional SITA Faster if \\> 2 tests were SITA Faster).\n8. Glaucoma definition will be based on VF damage (24-2, any SITA strategy) and spatially congruent glaucomatous changes at the ONH. If both eyes are eligible, the eye with the better MD will be chosen as the study eye.\n9. Women of childbearing potential willing to use an appropriate method of contraception.\n\nExclusion Criteria:\n\n1. Cataract in the study eye which, in the opinion of the clinician, may require cataract surgery within the next three years.\n2. Only-eye patients (visual acuity \\\u003C 0.1 decimals in one eye or more than two paracentral VF locations with a sensitivity of \\\u003C 10 dB).\n3. Known intolerance or allergy to any of the components in the eye drops.\n4. Diode laser treatment or glaucoma surgery in the past 2 years or cataract surgery within the last 6 months in the study eye.\n5. Eyes with any type of glaucoma other than primary, pseudoexfoliative or pigmentary OAG.\n6. Patients with other ocular or systemic comorbidities that, in the opinion of the Investigator, might affect the VF or the execution of the test.\n7. Patients already on topical or systemic citicoline treatment.\n8. Patients taking other systemic or topical potential neuroprotectors competing with citicoline eye drops 2% (a list will be provided) unwilling to suspend these treatments and undergo a washout period of 6 months prior to the study.\n9. Patients unable to perform reliable VF tests, based on the assessment of the last 4 available 24-2 Humphrey Field Analyzer (HFA) VF tests performed in the clinic with a false positive rate (FP) ≤ 15%.\n10. Pregnant and nursing patients.",{"count":503,"type":20},1000,[480],"To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%",[26],[55,508,509,510],"Citicoline","Visual field","Open-Angle glaucoma","2024-03-08",{"date":513,"type":31},"2024-03-12",{"date":515,"type":31},"2023-12-11",{"date":517,"type":20},"2027-04-01",{"name":519,"class":38},"Omikron Italia S.r.l.",{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":21,"phases":529,"briefSummary":530,"conditions":531,"keywords":532,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":544},"100470094","phase-3-bioequivalence-study-with-clinical-endpoint-comparing-bimatoprost-ophthalmic-solution-001-and-lumigan-in-the-treatment-of-chronic-open-angle-glaucoma-or-ocular-hypertension-in-both-eyes-100470094","NCT05401357","Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.","A Randomized, Double-blind, Multiple Dose, Parallel-group, Two-arm, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes","Inclusion Criteria:\n\n* Subjects willing and able to provide voluntary informed consent and to follow protocol requirements.\n* Male or females aged ≥18 years.\n* Subjects having body mass index (BMI) ≥18.50 kg\u002Fm2.\n* Subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.\n* Subjects requiring treatment of both eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.\n* Adequate washout period prior to baseline of any ocular hypotensive medications as per the table below (to minimize potential risk to subjects due to intraocular pressure (IOP) elevations during the washout period, the Investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandin; however, all the subjects must have discontinued their ocular hypotensive medications for the minimum washout period.\n* Baseline (Day 0\u002Fhour 0) IOP ≥22 mm Hg and \\\u003C35 mm Hg in each eye,\n* Subjects' IOP is likely to be controlled with monotherapy as per the Investigator's discretion.\n* Baseline best corrected visual acuity equivalent to Snellen acuity of 20\u002F100 or better in each eye, using a logarithmic visual acuity chart for testing at 10 feet (3 meters).\n* Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the dosing of the study drug) practicing any of the following acceptable methods of contraception:\n\n  1. Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication\n  2. Intrauterine device (IUD) or intrauterine system (IUS)\n  3. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)\n  4. Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)\n  5. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation\n  6. Total abstinence; partial abstinence is not acceptable\n* No history of addiction to any recreational drug or drug dependence or alcohol addiction.\n\nExclusion Criteria:\n\n* Female who are pregnant, lactating or planning a pregnancy.\n* Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation.\n* Current or past history of severe hepatic or renal impairment.\n* Current or history within 2 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts as per the Investigator's discretion will be allowed provided that the other inclusion\u002Fexclusion criteria are met).\n* Current corneal abnormalities that would prevent accurate IOP readings with Goldmann applanation tonometer.\n* Functionally significant visual field loss in the Investigators' opinion.\n* Subject with corneal grafts.\n* Subject has contraindication to pupil dilation\n* Use at any time prior to baseline of an intraocular corticosteroid implant\n* Use of contact lens within 1 week prior to baseline\n* Use within 2 weeks prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid\n* Use within 1 month prior to baseline of 1) a systemic corticosteroid or 2) high dose salicylate therapy defined as 325 mg\u002Fday and taken on 3 consecutive days.\n* Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid\n* Underwent within 6 months prior to baseline any other intraocular surgery (e.g., cataract surgery).\n* Underwent within 12 months prior to baseline any refractive surgery, filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty).\n* Amblyopia - only one sighted eye.\n* Subjects with a history of IOP previously uncontrolled on bimatoprost monotherapy\n* Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination\n* Severe retinal disease or other severe ocular pathology, such as glaucomatous damage with a cup\u002Fdisk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion) or split fixation\n* Chronic use of any systemic medication that may affect IOP with less than 3 months stable dosing regimen (i.e., sympathomimetic agents, beta-adrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.)\n* Central Corneal thickness (CCT) \\\u003C450 microns or \\>650 microns\n* Known history or presence of any uncontrolled systemic disease (e.g., cardiovascular disease, hypertension, diabetes mellitus, hepatic impairment, etc.)\n* History of recurrent ocular seasonal allergies within the past 2 years\n* Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements\n* Participation in any clinical study within 90 days before the first dose of the study drug\n* Subjects with documented history of positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection\n* Subjects with positive urine pregnancy test\n* Subjects with confirmed novel coronavirus infection (COVID-19).",{"count":528,"type":20},168,[480],"This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes.\n\nTest Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.",[26,310],[533,534],"Bimatoprost ophthalmic solution 0.01% in both eyes","Chronic open-angle glaucoma in both eyes","2022-08-09",{"date":537,"type":31},"2022-08-10",{"date":539,"type":31},"2022-06-29",{"date":541,"type":20},"2022-12",{"name":543,"class":38},"Amneal Pharmaceuticals, LLC",9]